Challenges and Chances in the Preclinical to Clinical Translation of Anticancer Metallodrugs
- Author(s)
- Isabella Pötsch, Dina Baier, Bernhard Keppler, Walter Berger
- Abstract
Despite being “sentenced to death” for quite some time, anticancer platinum compounds are still the most frequently prescribed cancer therapies in the oncological routine and recent exciting news from late-stage clinical studies on combinations of metallodrugs with immunotherapies suggest that this situation will not change soon. It is perhaps surprising that relatively simple molecules like cisplatin, discovered over 50 years ago, are still widely used clinically, while none of the highly sophisticated metal compounds developed over the last decade, including complexes with targeting ligands and multifunctional (nano)formulations, have managed to obtain clinical approval. In this book chapter, we summarize the current status of ongoing clinical trials for anticancer metal compounds and discuss the reasons for previous failures, as well as new opportunities for the clinical translation of metal complexes.
- Organisation(s)
- Department of Inorganic Chemistry
- External organisation(s)
- Medizinische Universität Wien, Research Cluster Translational Cancer Therapy Research
- Pages
- 308 - 347
- No. of pages
- 40
- DOI
- https://doi.org/10.1039/9781788016452-00308
- Publication date
- 04-2019
- Peer reviewed
- Yes
- Austrian Fields of Science 2012
- 104003 Inorganic chemistry, 301904 Cancer research
- ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology (miscellaneous)
- Sustainable Development Goals
- SDG 3 - Good Health and Well-being
- Portal url
- https://ucrisportal.univie.ac.at/en/publications/12600f53-5b32-4bef-b3f4-ad7ba4444829